Mithramycin oxime and hydrazine derivatives having increased selectivity and anti-cancer activity
US-2020131218-A1 · Apr 30, 2020 · US
Mithramycin oxime derivatives having increased selectivity and anti-cancer activity
US12486300B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12486300-B2 |
| Application number | US-202217963537-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 11, 2022 |
| Priority date | Oct 31, 2018 |
| Publication date | Dec 2, 2025 |
| Grant date | Dec 2, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds described herein are mithramycin (MTM) oxide (OX) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.
First claim
Opening claim text (preview).
What is claimed is: 1 . A compound having the following formula: or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of substituted or unsubstituted amino acid, amino acid dipeptide, acyl-amino acid, and acyl-amino acid dipeptide. 2 . The compound of claim 1 , wherein R is acyl-amino acid or acyl-amino acid dipeptide. 3 . The compound of claim 1 , wherein R is substituted acyl-amino acid or acyl-amino acid dipeptide. 4 . The compound of claim 1 , wherein R is a substituted amino acid, amino acid dipeptide, acyl-amino acid, and acyl-amino acid dipeptide, wherein the substitution is a quinolone, a benzothizole, a phenyl, a pyridine, or an indol group. 5 . The compound of claim 1 , wherein R is an amino acid or amino acid dipeptide group, or a substituted amino acid or amino acid dipeptide group. 6 . A method of treating Ewing sarcoma, prostate cancer, colon cancer, lung cancer, leukemia, and/or lymphoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of claim 1 . 7 . The method of claim 6 , wherein the method comprises treating Ewing sarcoma. 8 . The method of claim 6 , wherein the method comprises treating prostate cancer. 9 . The method of claim 6 , wherein the method comprises treating colon cancer. 10 . The method of claim 6 , wherein the method comprises treating lung cancer. 11 . The method of claim 6 , wherein the method comprises treating leukemia or lymphoma. 12 . A method for selectively inhibiting EWS-FLI1 transcription factors in a patient in need thereof, including administering to the patient a therapeutically effective amount of the compound of claim 1 .
Assignees
Inventors
Classifications
Acyclic or carbocyclic radicals, substituted by hetero rings · CPC title
- A61P35/00Primary
Antineoplastic agents · CPC title
- C07H15/244Primary
Anthraquinone radicals, e.g. sennosides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12486300B2 cover?
- Compounds described herein are mithramycin (MTM) oxide (OX) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.
- Who is the assignee on this patent?
- Univ Kentucky Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).